Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts

Shares of Pfizer Inc. (NYSE:PFE) have been assigned an average rating of “Hold” from the twenty-one ratings firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $28.2778.

Several research analysts have issued reports on PFE shares. Wolfe Research reissued an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Guggenheim lowered their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Bank of America cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research report on Tuesday, June 9th.

Pfizer Trading Up 1.9%

NYSE:PFE opened at $26.70 on Friday. The company has a market cap of $152.20 billion, a PE ratio of 35.14 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.71. The company has a 50 day simple moving average of $25.02 and a two-hundred day simple moving average of $26.16. Pfizer has a 12 month low of $23.58 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the firm earned $0.78 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts forecast that Pfizer will post 2.97 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently bought and sold shares of PFE. Brighton Jones LLC raised its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares in the last quarter. United Bank raised its holdings in Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares during the period. Sei Investments Co. lifted its position in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC boosted its stake in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Better-than-expected Q2 results supported the stock. Pfizer reported adjusted EPS of $0.77 versus the $0.68 consensus estimate and revenue of $15.03 billion versus expectations of $14.40 billion. The company also raised its 2026 revenue outlook, helping offset concerns about declining COVID-related sales. Pfizer Inc. Q2 2026 Earnings Call Summary
• Positive Sentiment: Pipeline progress is improving Pfizer’s longer-term outlook. Analysts highlighted the company’s broader pipeline, including the potential obesity treatment berobenatide and PF-07328948. Berobenatide is being compared with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, although Pfizer still faces significant development and competitive hurdles. Pfizer’s Next Weight-Loss Weapon
• Positive Sentiment: Pfizer and BioNTech advanced COVID-19 vaccine studies. A new Phase 4 study of a variant-adapted booster, along with progress on a next-generation pediatric booster, could support future vaccine demand and preserve the partnership’s commercial position. Variant-Adapted COVID-19 Booster Study
• Neutral Sentiment: Analyst opinion remains mixed. Some analysts are bullish after the earnings beat and pipeline updates, while RBC Capital maintained a Hold rating, indicating that valuation and execution risks continue to limit conviction. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: Patent expirations and obesity-program uncertainty remain overhangs. Investors are questioning whether Pfizer’s pipeline can replace revenue lost to upcoming patent cliffs, while previous obesity setbacks make the berobenatide opportunity particularly important but far from assured. Pfizer’s Patent and Pipeline Outlook
• Negative Sentiment: COVID product sales remain weak. Pfizer’s COVID pill revenue reportedly fell 95%, underscoring the company’s continuing dependence on non-COVID products and pipeline launches to drive growth. Pfizer COVID Pill Revenue Decline

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.